Saturday, October 31, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleMIT Technology Review

The scientist using AI to hunt for antibiotics just about everywhere

View original at technologyreview.com
MIT Technology Review - Ai Research Title: The scientist using AI to hunt for antibiotics just about everywhere Date: 2026-02-16 11:00 Source: https://www.technologyreview.com/2026/02/16/1132516/cesar-de-la-fuente-using-ai-antibiotics-hunt/ <p>When he was just a teenager trying to decide what to do with his life, César…
Opening lines of the source · MIT Technology Review · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • These peptides haven't yet been transformed into usable drugs that help people

    80% confidence
  • It's only been a few years since folks have been using AI meaningfully in drug discovery

    80% confidence
  • The use, overuse, and misuse of antibiotics drives antimicrobial resistance

    80% confidence
  • De la Fuente is marvelously talented, very innovative

    80% confidence
  • De la Fuente has really helped pioneer the space of harnessing AI for real-world problems

    80% confidence
  • Drug discovery in any domain is a statistics game. You need enough shots on goal to happen to get one

    80% confidence
  • This is the world that we live in today, and it's incredible

    80% confidence
  • AI has already saved decades of human research time

    80% confidence
  • Antimicrobial resistance deaths could surge past 8 million by 2050

    80% confidence
  • Many companies that attempted antibiotic development have folded because there's no good return on investment

    80% confidence
  • Researchers have moved from using predictive models to developing generative approaches

    80% confidence
  • Antimicrobial resistance is an almost impossible problem

    80% confidence
  • The world of antibiotic development needs as much creativity and innovation as researchers can muster

    80% confidence
  • The antibiotic discovery pipeline remains perilously thin, impeded by high development costs, lengthy timelines, and low returns on investment

    80% confidence
  • Biology is an information source like a bunch of code

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com